{
    "clinical_study": {
        "@rank": "55540", 
        "brief_summary": {
            "textblock": "T Cell Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders are a heterogeneous\n      group of uncommon diseases which may involve a polyclonal or a monoclonal T cell population,\n      which bear characteristic surface markers corresponding to activated cytotoxic (CD3+, CD8+)\n      lymphocytes.  They are often associated with quite severe neutropenia, anemia, and\n      thrombocytopenia which may be life-threatening.  There is some evidence that the abnormal\n      cytotoxic lymphocyte population may cause the cytopenias by suppressing hematopoiesis,\n      although the mechanism is unclear.  Case reports suggest that immunosuppressive therapy\n      directed toward T cells may reverse the cytopenia.  This pilot study involving up to 25\n      patients evaluates the clinical response to cyclosporine, an immunosuppressive drug, and\n      seeks to elucidate the mechanism underlying the cytopenia."
        }, 
        "brief_title": "Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine", 
        "completion_date": "September 2000", 
        "condition": [
            "Anemia", 
            "Leukemia, T-Cell", 
            "Lymphocytosis", 
            "Neutropenia", 
            "Thrombocytopenia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Leukemia", 
                "Leukemia, T-Cell", 
                "Lymphocytosis", 
                "Lymphoproliferative Disorders", 
                "Neutropenia", 
                "Thrombocytopenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "T Cell Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders are a heterogeneous\n      group of uncommon diseases which may involve a polyclonal or a monoclonal T cell population,\n      which bear characteristic surface markers corresponding to activated cytotoxic (CD3+, CD8+)\n      lymphocytes.  They are often associated with quite severe neutropenia, anemia, and\n      thrombocytopenia which may be life-threatening.  There is some evidence that the abnormal\n      cytotoxic lymphocyte population may cause the cytopenias by suppressing hematopoiesis,\n      although the mechanism is unclear.  Case reports suggest that immunosuppressive therapy\n      directed toward T cells may reverse the cytopenia.  This pilot study involving up to 25\n      patients evaluates the clinical response to cyclosporine, an immunosuppressive drug, and\n      seeks to elucidate the mechanism underlying the cytopenia."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients must be greater than or equal to 18 years of age.\n\n        Peripheral blood absolute LGL count of greater than or equal to 300/ul (performed on a\n        manual differential), with LGL cells having the characteristic appearance of large\n        lymphocytes with abundant pale blue cytoplasm, with or without a perinuclear clear zone,\n        with varying degrees of azurophilic granules.\n\n        Immunophenotypic studies of peripheral blood showing an increased population of T-LGL\n        (Staining for: CD3, CD8, and either CD16 or CD57+/- CD56).\n\n        Severe neutropenia (less than or equal to 500 neutrophils/uL of peripheral blood), or\n        severe thrombocytopenia (less than or equal to 20,000 platelets/uL, or moderate\n        thrombocytopenia (less than or equal to 50,000 platelets/uL with active bleeding , or\n        anemia (hemoglobin less than or equal to 9 gm/dL), or red blood cell transfusion\n        requirement of greater than or equal to 2 units/month for two months prior to initiation\n        of CsA treatment.\n\n        Patients must not have had previous treatment with CsA or FK506.\n\n        Patients must not have a reactive LGL lymphocytosis to a viral infection.\n\n        Patients must not have a ECOG performance status of greater than 3.\n\n        Patients must not be currently pregnant, or unwilling to take oral contraceptives unless\n        postmenopausal.\n\n        Mothers must not be breast feeding.\n\n        Patients must be able to give informed consent.\n\n        Patients must not be HIV positive."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "25", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001533", 
            "org_study_id": "960142", 
            "secondary_id": "96-H-0142"
        }, 
        "intervention": {
            "intervention_name": "cyclosporine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine"
            ]
        }, 
        "keyword": [
            "Anemia", 
            "Chronic T Cell Lymphocytosis with Neutropenia", 
            "Immunosuppression", 
            "Neutropenia", 
            "T-LGL Leukemia"
        ], 
        "lastchanged_date": "July 14, 2006", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Heart, Lung and Blood Institute (NHLBI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "PMID": "8324214", 
                "citation": "Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993 Jul 1;82(1):1-14. Review."
            }, 
            {
                "PMID": "7920220", 
                "citation": "Witzig TE, Weitz JJ, Lundberg JH, Tefferi A. Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. Leuk Lymphoma. 1994 Jun;14(1-2):137-9."
            }, 
            {
                "PMID": "8562948", 
                "citation": "Gabor EP, Mishalani S, Lee S. Rapid response to cyclosporine therapy and sustained remission in large granular lymphocyte leukemia. Blood. 1996 Feb 1;87(3):1199-200. No abstract available."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001533"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "September 1996", 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1999"
    }, 
    "geocoordinates": {
        "National Heart, Lung and Blood Institute (NHLBI)": "38.985 -77.095"
    }
}